文献速递淋巴瘤

晚期霍奇金淋巴瘤的正电子发射断层扫描驱动策略:AHL2011 Ⅲ期淋巴瘤研究协会研究的延长随访

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
PubMed 文献 · J Clin Oncol · 2022-01-06

AHL2011研究纳入823例晚期霍奇金淋巴瘤患者,随机分为标准6周期BEACOPP组与PET驱动组(2周期BEACOPP后PET2-者接受4周期ABVD,PET2+者接受4周期BEACOPP)。中位随访67.2个月,两组5年PFS和OS相似。延长随访证实PET驱动策略非劣效于标准6周期BEACOPP,PET4提供额外预后信息。

要点

  • 中位随访67.2个月,标准组与PET驱动组5年PFS分别为87.5%与86.7%(HR=1.07,95%CI 0.74-1.57,P=.67)。
  • 两组5年OS均为97.7%(HR=1.012,95%CI 0.50-2.10,P=.53)。
  • 全队列中PET2-/PET4-者5年PFS为92.3%,PET2+/PET4-者为75.4%,PET4+者为46.5%(P<.0001)。

核心结论

  • 延长随访证实AHL2011 PET驱动策略持续有效且安全性良好,非劣效于标准6周期BEACOPP。
  • PET4在PET2基础上提供额外预后信息,可识别预后特别差的患者。

研究设计与样本

  • AHL2011研究(ClinicalTrials.gov标识符NCT01358747)为前瞻性随机Ⅲ期研究。
  • 纳入年龄16-60岁晚期霍奇金淋巴瘤患者(Ⅲ期、Ⅳ期或纵隔/胸腔比>0.33或结外受累的ⅡB期)。
  • 共入组823例,标准组413例,PET驱动组410例。
  • 标准组接受6×BEACOPP;PET驱动组在2×BEACOPP后,PET2-者接受4×ABVD,PET2+者接受4×BEACOPP。
  • 化疗4周期后PET须阴性方可完成计划治疗。

主要发现

  • 中位随访67.2个月,5年PFS标准组87.5% vs PET驱动组86.7%(HR=1.07;95%CI 0.74-1.57;P=.67)。
  • 5年OS两组均为97.7%(HR=1.012;95%CI 0.50-2.10;P=.53)。
  • 全队列中,5年PFS在PET2-/PET4-者为92.3%,PET2+/PET4-者为75.4%(HR=3.26;95%CI 18.3-5.77),PET4+者为46.5%(HR=12.4;95%CI 7.31-19.51)(P<.0001),独立于国际预后评分。
  • 5年OS亦受中期PET结果影响:PET2+/PET4-者为93.5%(HR=3.3;95%CI 1.07-10.1;P=.036),PET4+者为91.9%(HR=3.756;95%CI 1.07-13.18;P=.038),均显著低于PET2-/PET4-者的98.2%。
  • 第二原发恶性肿瘤共22例(2.7%),标准组13例(3.2%),实验组9例(2.2%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and reduces early toxicity compared with a nonmonitored standard treatment. Here, we report, with a prolonged follow-up, the final study results. METHODS: Patients with advanced Hodgkin lymphoma (stage III, IV, or IIB with mediastinum/thorax ratio > 0.33 or extranodal involvement) age 16-60 years were prospectively randomly assigned between 6 × BEACOPP and a PET-driven arm after 2 × BEACOPP delivering 4 × ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in PET2- and 4 × BEACOPP in PET2+ patients. PET performed after four cycles of chemotherapy had to be negative to complete the planned treatment. RESULTS: In total, 823 patients were enrolled including 413 in the standard arm and 410 in the PET-driven arm. With a 67.2-month median follow-up, 5-year PFS (87.5% v 86.7%; hazard ratio [HR] = 1.07; 95% CI, 0.74 to 1.57; P = .67) and OS (97.7% in both arms; HR = 1.012; 95% CI, 0.50 to 2.10; P = .53) were similar in both randomization arms. In the whole cohort, full interim PET assessment predicted patients' 5-year PFS (92.3% in PET2-/PET4-, 75.4% [HR = 3.26; 95% CI, 18.3 to 5.77] in PET2+/PET4- and 46.5% [HR = 12.4; 95% CI, 7.31 to 19.51] in PET4+ patients, respectively; P < .0001) independent of international prognosis score. Five-year OS was also affected by interim PET results, and PET2+/PET4- patients (93.5%; HR = 3.3; 95% CI, 1.07 to 10.1; P = .036) and PET4+ patients (91.9%; HR = 3.756; 95% CI, 1.07 to 13.18; P = .038) had a significant lower OS than PET2-/PET4- patients (98.2%). Twenty-two patients (2.7%) developed a second primary malignancy, 13 (3.2%) and 9 (2.2%) in the standard and experimental arms, respectively. CONCLUSION: The extended follow-up confirms the continued efficacy and favorable safety of AHL2011 PET-driven strategy, which is noninferior to standard six cycles of BEACOPP. PET4 provides additional prognostic information to PET2 and allows identifying patients with particularly poor prognosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Casasnovas RO, Bouabdallah R, Brice P, et al. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. J Clin Oncol. 2022. PMID: 34990281. doi:10.1200/JCO.21.01777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。